Eli Lilly stops disclosing Phase 1 pipeline, making early-stage projects invisible in earnings decks

Eli Lilly has become more opaque as its size grows, choosing to stop public disclosure of its early-stage research efforts. The shift was noted earlier this year when the company removed Phase 1 projects from its earnings presentation.

The removal means that investors and analysts no longer see detailed information about the drugmaker's newest candidates in its public reports. This lack of visibility limits the ability to assess the future pipeline and potential value creation.

Analysts suggest the move could reflect a strategic decision to protect competitive information, but it also raises concerns about transparency for shareholders who rely on pipeline data for investment decisions.

The observation was reported by Post‑Hoc, which highlighted the change without providing additional context or commentary on the reasons behind the new policy.